Mass Tort Glossary

Administrative Claims Handling

Administrative claims handling refers to the post-settlement process through which a claims administrator evaluates each plaintiff's submission against the settlement's eligibility and compensation criteria, assigns a tier or payment amount under the agreed grid, resolves disputes, and ultimately issues payments. In large MDLs, claims administration may involve processing tens of thousands of individual claim packages, coordinating lien resolution across multiple payors, and managing an appeals process for claimants who dispute their tier assignments. The pace and quality of claims administration directly affect a funder's time to repayment — inefficient administrators, unclear eligibility criteria, or high dispute rates can extend the post-settlement distribution period by 18–36 months beyond initial expectations. Funders with large docket exposure routinely monitor claims administration progress and, in some cases, provide additional capital to fund administrative overhead in exchange for priority distribution.

Bellwether Trial

A bellwether trial is a representative individual case selected from a mass tort docket and tried to verdict for the purpose of generating data points that inform global settlement negotiations. The MDL transferee judge typically selects bellwether cases through a combination of plaintiff and defense picks designed to produce a statistically meaningful sample of claim types, injury severities, and plaintiff demographics. Bellwether outcomes do not bind other claimants, but they function as pricing anchors — a string of plaintiff verdicts signals that the defendant's liability exposure is real and tends to accelerate settlement pressure and increase per-claimant compensation grids. For litigation funders, bellwether scheduling represents a key liquidity event horizon, and adverse bellwether results can require capital reserve adjustments across an entire portfolio.

CAFA (Class Action Fairness Act)

The Class Action Fairness Act of 2005 expanded federal jurisdiction over class actions and mass actions by granting federal courts original jurisdiction over cases with more than 100 plaintiffs where the aggregate amount in controversy exceeds $5 million and minimal diversity exists between any plaintiff and any defendant. CAFA effectively moved large, multi-state class litigation from state courts — where plaintiffs historically enjoyed more favorable certification standards — into federal courts, accelerating the shift toward MDL as the preferred vehicle for coordinating large personal injury dockets. For litigation funders, CAFA jurisdiction determinations matter because they establish whether a docket proceeds in federal court (subject to MDL consolidation) or remains in state court (potentially in a plaintiff-favorable jurisdiction), which materially affects settlement leverage and recovery probability. Mass tort funders must also assess whether their funded docket is at risk of CAFA-based removal challenges that could disrupt state court coordination strategies.

Claim Aggregator

A claim aggregator is a law firm, litigation finance vehicle, or case acquisition platform that systematically assembles large volumes of mass tort claims — typically through attorney referral networks, advertising, or co-counsel arrangements — for the purpose of achieving scale and negotiating leverage in global settlement discussions. Aggregators may represent thousands of claimants across a single MDL and can exert material influence over settlement timing and pricing through their ability to credibly commit or withhold large claim blocks. From a funder's perspective, investing at the aggregator level offers portfolio diversification and operational efficiency, but introduces concentration risk and alignment concerns — an aggregator's incentive to maximize aggregate settlement speed may not be perfectly aligned with maximizing individual claimant recovery. Funders providing capital to aggregators typically require transparency into claim-level data, enrollment thresholds, and settlement authority parameters.

Class Action vs. Mass Tort Distinction

The fundamental distinction between a class action and a mass tort lies in whether plaintiffs are represented collectively under a single certified class (class action) or individually through separate lawsuits coordinated for pretrial purposes (mass tort). In a certified class action, a class representative litigates on behalf of all class members, and a single judgment or settlement binds everyone who does not opt out; in a mass tort, each plaintiff must independently prove causation and damages and retains individual settlement authority. This structural difference has profound litigation finance implications: class action funding typically targets common fund fee recoveries paid to plaintiffs' counsel, while mass tort funding engages both PSC-level common benefit financing and individual claim-level capital advances. The inability to certify a damages class — which courts have consistently refused for mass personal injury torts since Amchem — is the primary driver of MDL as the dominant federal consolidation mechanism for large-scale product liability litigation.

Common Benefit Fee

A common benefit fee is the compensation paid to PSC attorneys from the common benefit fund in recognition of legal work that created value for all plaintiffs on the docket, regardless of which firm retained each individual client. Courts apply a lodestar or percentage analysis to determine appropriate common benefit awards, with successful MDLs generating common benefit fees in the hundreds of millions of dollars on large pharmaceutical or product liability dockets. Litigation funders targeting PSC-level investments price their capital against expected common benefit fee flows, which are generally senior in priority and more predictable than individual claim recoveries. The risk in common benefit fee financing is primarily execution risk — PSC firms must actually perform the work, survive Daubert challenges, and drive the docket to resolution before fee entitlements vest.

Common Benefit Fund

A common benefit fund is a court-supervised account into which a percentage of each plaintiff's recovery is deposited to compensate PSC attorneys for the legal work that benefited all claimants on the docket — discovery, expert retention, motion practice, and bellwether preparation. The transferee court sets the holdback percentage, typically ranging from 4% to 8% of gross recoveries, and the fund is distributed among contributing firms through a fee allocation process. From a litigation finance perspective, the common benefit assessment is a structural cost that funders must factor into their recovery modeling — a 6% common benefit hold reduces effective net proceeds and therefore affects the return multiple on capital deployed at the individual claim level. Funders providing PSC-level capital sometimes structure their return as a percentage of the common benefit fund rather than individual claim proceeds.

Defendant Class Action

A defendant class action is an unusual procedural mechanism under Rule 23 in which a class of defendants — rather than plaintiffs — is certified and bound by a single judgment, most commonly employed in cases involving a diffuse group of similarly situated defendants such as franchisees, retailers, or government entities. Defendant class actions are rare in mass tort contexts but occasionally arise in environmental or product distribution cases where liability is alleged against multiple entities with common defenses. From a litigation finance perspective, defendant class certification can simplify the recovery landscape by concentrating liability and settlement authority, but it also raises complex due process and adequacy of representation concerns that frequently generate appellate risk. Funders evaluating cases where defendant class certification has been proposed should treat the certification ruling as a binary event with significant impact on recovery timeline and certainty.

Global Settlement

A global settlement in the mass tort context is a negotiated resolution in which a defendant agrees to pay an aggregate sum to resolve all or substantially all pending and future claims arising from the challenged conduct, typically administered through a claims facility. Unlike individual settlements, global settlements require coordinated opt-in participation from a critical mass of plaintiffs — often 85–95% of enrolled claimants — before the defendant will fund the settlement. The structure of a global settlement directly determines funder returns: aggregate fund size, allocation methodology, and the pace of claims administration all affect net present value. Funders underwriting claims in anticipation of a global settlement must model the probability that enrollment thresholds will be met and that their funded claimants will qualify under the settlement's eligibility criteria.

Government Enforcement vs. Private Plaintiff

In mass tort-adjacent litigation, government enforcement actions brought by state attorneys general, the Department of Justice, or regulatory agencies pursue public remedies — injunctions, civil penalties, disgorgement, and consumer restitution — while private plaintiff litigation seeks individual and aggregate compensatory damages for personal injury or economic harm. The two tracks frequently run in parallel, and government settlements can both accelerate private plaintiff resolution (by establishing liability findings and creating settlement precedent) and complicate it (by consuming defendant financial capacity and imposing injunctive terms that affect ongoing business). For litigation funders, the interaction between government and private tracks is a structural portfolio risk: a DOJ settlement that requires corporate behavioral changes may preserve defendant solvency and facilitate private claims resolution, while a criminal plea or debarment can impair the defendant's ability to fund a private settlement fund. Funders with exposure to both tracks should model the sequencing and cross-collateral effects of government resolution before the private track closes.

Grid Settlement

A grid settlement is a structured compensation framework used in mass tort global settlements that assigns each plaintiff to a predetermined payment tier based on objective criteria — typically injury severity, product exposure duration, age at diagnosis, and the presence of aggravating or mitigating factors. Grids eliminate the need for individual damages negotiation across thousands of claims, enabling efficient administration through a claims facility, but they also cap recovery for plaintiffs with outlier injuries who might have fared better in individual litigation. For litigation funders, the existence and terms of a negotiated settlement grid are a primary recovery modeling input — once a grid is agreed, recovery ranges for the funded claim cohort become much more predictable, allowing funders to mark their portfolios with higher confidence. Funders with large claim exposure in a docket sometimes negotiate to participate in grid design discussions through PSC relationships.

Lead Law Firm

A lead law firm in an MDL is a plaintiff's firm that has accumulated sufficient claim volume and courtroom experience to assume a directing role in docket strategy, PSC participation, and settlement negotiations, often functioning as the de facto principal even when nominally co-equal with other PSC members. Lead firms typically absorb the largest share of common benefit costs and carry the greatest reputational and financial risk if the docket resolves poorly, but they also capture the largest share of common benefit fee awards. For litigation funders, a lead firm with a demonstrated history of taking MDL dockets to resolution — particularly through bellwether trial cycles — is a materially stronger credit than a firm with only settlement experience. The lead firm's financial capacity to sustain multi-year common benefit expenditures without external capital is itself a proxy for docket health and settlement probability.

Lien Resolution

Lien resolution refers to the process of identifying, negotiating, and satisfying third-party claims against a plaintiff's settlement proceeds — including Medicare and Medicaid reimbursement demands, private health insurer subrogation claims, workers' compensation liens, and litigation funding repayment obligations. In large MDLs, lien resolution is typically outsourced to specialized administrators and can take 12–24 months after settlement funds are deposited, creating material delay between gross settlement and net distribution to plaintiffs and their attorneys. For funders, unresolved or unexpectedly large liens are a recovery impairment risk — a plaintiff who settles for $500,000 may net substantially less after lien satisfaction, reducing the proceeds available to repay litigation funding advances. Funder due diligence should assess the anticipated lien profile of the funded plaintiff cohort before committing capital.

Mass Tort

A mass tort arises when a single product, event, or course of conduct causes similar injuries to a large number of plaintiffs, each of whom retains an individual legal claim rather than a unified class action. Unlike a class action, every plaintiff in a mass tort must prove causation and damages separately, which preserves individual recovery potential but creates enormous coordination and financing demands. From a funder's perspective, mass torts represent portfolio-level exposure — capital is typically deployed across hundreds or thousands of claims simultaneously, and returns depend on aggregate settlement outcomes rather than any single verdict. The combination of long duration (often 5–10 years from filing to distribution) and high upfront common benefit costs makes early-stage litigation finance structurally essential for most mass tort campaigns.

Mass Tort Docket Financing

Mass tort docket financing is the practice of providing institutional capital to a law firm, claim aggregator, or PSC to fund the total cost of developing and resolving a large portfolio of related mass tort claims — encompassing client acquisition, case development, common benefit contributions, and operating expenses — in exchange for a return structured as a multiple of invested capital or a percentage of aggregate net recoveries. Unlike single-case financing, docket financing treats the entire portfolio as the funded asset, with individual claim variability diversified across thousands of positions and returns driven by aggregate docket performance rather than any individual outcome. Docket financing terms typically include minimum enrollment thresholds, concentration limits by injury type or state, consent rights over global settlement decisions above certain thresholds, and provisions governing the treatment of early voluntary dismissals. For institutional funders, mass tort docket financing offers scalable deployment of capital in the $50M–$500M range that is difficult to achieve through single-matter investments, but requires deep operational expertise in MDL docket management and claims administration to underwrite effectively.

MDL Financing Structure

MDL financing structure refers to the architecture of litigation capital deployed across a multi-district litigation docket, which typically operates on at least two distinct levels: PSC or common benefit financing, which funds the shared costs of discovery, experts, and case development, and individual claim financing, which advances working capital to law firms or plaintiffs against anticipated individual recoveries. Some large MDL financings also include a mezzanine layer that funds the lead firm's overhead and client acquisition costs, creating a three-tranche capital stack with different seniority, return profiles, and event triggers. Because common benefit costs are incurred years before any settlement, and individual claim proceeds are only realized at the end of a 5–10 year docket lifecycle, MDL financing structures must be designed with long duration tolerance, milestone-based funding tranches, and clear waterfall provisions that address the interaction between common benefit assessments, lien satisfaction, and funder repayment. This complexity makes MDL financing one of the most sophisticated and high-value segments of the litigation finance market.

MDL Transferee Court

The MDL transferee court is the federal district court designated by the Judicial Panel on Multidistrict Litigation to receive and oversee consolidated pretrial proceedings for a given MDL docket. The assigned judge — the transferee judge — exercises extraordinary case management authority, including setting bellwether trial schedules, ruling on global Daubert motions, and applying pressure toward global settlement. Because transferee judges vary significantly in their appetite for trial, speed of docket management, and receptiveness to plaintiffs' theories, the identity of the transferee court is a primary underwriting variable for mass tort funders. A docket assigned to a judge known for aggressive bellwether scheduling and plaintiff-favorable evidentiary rulings commands a materially different risk premium than one sitting in a court with a historically slow, defense-friendly posture.

Medicare Set-Aside

A Medicare Set-Aside (MSA) is a designated allocation within a personal injury settlement intended to pay for future medical expenses related to the settled injury that would otherwise be covered by Medicare, preserving Medicare's secondary payer status and protecting the settling parties from future reimbursement liability. In mass tort settlements, MSA requirements can significantly reduce the net cash available to claimants and create complex administrative obligations that extend settlement timelines. Funders must account for MSA requirements in their underwriting because mandatory set-asides reduce the distributable settlement fund and may trigger CMS review and approval processes that delay disbursement by 6–18 months. Failure to properly structure MSAs exposes claimants, law firms, and in some cases funders to federal recovery actions by CMS for conditional payments made after settlement.

Multi-District Litigation (MDL)

Multi-district litigation is a federal procedural mechanism under 28 U.S.C. § 1407 that consolidates civil actions sharing common questions of fact before a single transferee judge for coordinated pretrial proceedings. MDL does not merge the underlying cases — each plaintiff's claim remains legally distinct — but it centralizes discovery, expert testimony, and dispositive motion practice to eliminate duplicative effort across federal courts. For litigation funders, MDL consolidation is a threshold structural event: it determines the forum, the judge, and the pace of the entire docket, each of which materially affects deployment timelines and recovery probabilities. Funders evaluating MDL investments must assess the transferee court's historical resolution speed and the MDL Panel's assignment patterns, since forum selection at this stage is largely non-negotiable.

Parens Patriae

Parens patriae is a legal doctrine under which a state government brings litigation on behalf of its citizens to recover for harms caused to the public at large, asserting the state's sovereign interest in the welfare of its residents rather than requiring individual claimants to sue separately. State attorneys general have used parens patriae extensively in mass tort-adjacent litigation — opioid manufacturer suits, tobacco litigation, and pharmaceutical pricing cases — with aggregate recoveries that rival the largest private MDL settlements. From a litigation finance perspective, parens patriae claims by state AGs are an attractive funding target because they are prosecuted by well-resourced state offices, carry strong political motivation, and tend to resolve through large negotiated agreements rather than verdict risk. Funders providing capital to contingency-fee outside counsel retained by state AGs must navigate specific ethical and public records constraints that differ materially from private plaintiff financing.

Plaintiff Fact Sheet (PFS)

A Plaintiff Fact Sheet is a standardized questionnaire required of each plaintiff in an MDL, capturing medical history, product exposure, alleged injuries, and damages information in a uniform format established by the transferee court. PFS completion is typically a prerequisite to maintaining active status on the docket, and deficient or non-responsive PFS submissions can result in dismissal of individual claims. For funders with portfolio exposure across large MDL dockets, PFS compliance rates are an operational risk factor — a high rate of dismissals for PFS deficiency can impair the funded claim pool and reduce aggregate recovery. Due diligence on any mass tort investment should include an assessment of the law firm's infrastructure for client communication, records collection, and PFS submission compliance.

Plaintiff Steering Committee (PSC)

A Plaintiff Steering Committee is the court-appointed leadership structure within an MDL, composed of plaintiff attorneys authorized to conduct discovery, retain common experts, and negotiate on behalf of the entire plaintiff cohort. PSC members are typically the largest and most experienced firms on the docket; they bear the common benefit costs and are entitled to a common benefit fee assessed against all recoveries. From a litigation finance perspective, the PSC composition is a critical due diligence input — well-resourced PSC leadership with deep MDL experience signals faster resolution and stronger negotiating leverage, while underfunded PSCs frequently turn to institutional capital to finance common benefit work. Funders providing PSC-level financing often receive preferred return structures in exchange for the systemic risk of funding the entire docket's development.

Qualified Settlement Fund (QSF)

A Qualified Settlement Fund is a trust or escrow account established under Treasury Regulation § 1.468B-1 that receives settlement proceeds from defendants and holds them pending resolution of claims, lien satisfaction, and distribution to plaintiffs. The QSF structure allows defendants to obtain a complete tax deduction for their settlement contribution at the time of payment, even before individual claimants receive their distributions, which frequently accelerates defendant participation in global settlements. From a litigation finance perspective, the establishment of a QSF is a critical milestone — it signals that the defendant has committed funds to resolution and that the docket has entered the administrative phase, at which point funder recovery becomes a near-term operational exercise rather than a contested legal risk. QSF administrators handle lien resolution, fee disbursements, and structured settlement arrangements, and their efficiency materially affects the time from settlement to net distribution.

Science Day

Science day is an informal presentation held before an MDL transferee judge in which both sides' scientific and medical experts present the core causation evidence before any Daubert motions are filed, allowing the judge to develop foundational familiarity with the science at issue. These sessions are not evidentiary hearings, but they are highly consequential: a judge who comes away skeptical of plaintiffs' causation theory may apply heightened scrutiny to Daubert motions and significantly narrow the plaintiff cohort. Litigation funders often treat the post-science-day period as a pricing inflection point — unfavorable judicial signals following science day can depress settlement values and trigger portfolio revaluation. Conversely, a strong plaintiff presentation at science day can accelerate defendant settlement posture by signaling that Daubert challenges will not eliminate the docket.

Structured Settlement

A structured settlement is a resolution mechanism in which a portion or all of a plaintiff's compensation is paid over time through a series of periodic payments, typically funded by an annuity purchased from a life insurance company, rather than as a single lump-sum payment. Structured settlements are common in cases involving serious personal injury, particularly where ongoing medical care or lost income must be funded, and in many jurisdictions they provide plaintiffs with tax advantages on investment income within the annuity. For litigation funders who have advanced capital against an eventual lump-sum recovery, a structured settlement creates a repayment timing mismatch — funders typically require repayment from the present-value lump-sum equivalent or negotiate priority repayment from the initial payment tranche. The interaction between litigation funding agreements and structured settlement annuities requires careful drafting to ensure enforceability and timing alignment.

Subrogation

Subrogation is the legal right of a third-party payor — such as a health insurer, ERISA plan, or government program — to recover from a tort settlement the amounts it paid for medical treatment of injuries caused by the defendant. In mass tort litigation, subrogation claims from private insurers and government payors can consume a significant fraction of individual settlement proceeds, particularly for claimants with serious injuries who have received expensive treatment. ERISA-governed plans have particularly strong subrogation rights under federal law and may assert dollar-for-dollar reimbursement without equitable reduction, a feature that distinguishes them from state-law subrogation claims. Litigation funders underwriting mass tort claims must model expected subrogation exposure as a first-priority claim against settlement proceeds that ranks ahead of funding repayment in most settlement waterfall structures.